We believe that automation of our galectin-3 test will broaden its acceptance by laboratory customers and, as a result, accelerate its clinical adoption. To that end, we have entered into licensing and commercialization agreements with four leading diagnostic instrument manufacturers to develop and commercialize automated instrument versions of our galectin-3 test. We have entered into worldwide license, development and commercialization agreements with Abbott Laboratories, or Abbott, bioMérieux SA, or bioMérieux, Siemens Healthcare Diagnostics Inc., or Siemens, and Alere Inc., or Alere. These diagnostic instrument manufacturers account for a significant percentage of the automated laboratory testing instruments that are used throughout the world. The installed customer base of these automated partners reflects all major segments of the diagnostics market including hospital laboratories, national reference laboratories, regional laboratories and others.
Company profile
Ticker
BGMD
Exchange
Website
CEO
Paul R. Sohmer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
43506204
Latest filings (excl ownership)
DEF 14A
Definitive proxy
23 Jun 16
15-12B
Securities registration termination
5 May 16
CT ORDER
Confidential treatment order
4 May 16
10-K/A
2015 FY
Annual report (amended)
29 Apr 16
10-K
2015 FY
Annual report
4 Apr 16
8-K
Results of Operations and Financial Condition
31 Mar 16
EFFECT
Notice of effectiveness
31 Mar 16
NT 10-K
Notice of late annual filing
31 Mar 16
POS AM
Prospectus update (post-effective amendment)
29 Mar 16
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 16
Latest ownership filings